至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

An E460D Substitution in the NS5 Protein of Tick-Borne Encephalitis Virus Confers Resistance to the Inhibitor Galidesivir (BCX4430) and Also Attenuates the Virus for Mice

J Virol. 2020-07; 
Eyer L, Nougairède A, Uhlířová M, Driouich JS, Zouharová D, Valdés JJ, Haviernik J, Gould EA, De Clercq E, de Lamballerie X, Ruzek D.
Products/Services Used Details Operation
PCR Cloning and Subcloning Three de novo-synthesized DNA fragments cloned into a pUC57 vector were used in this study (GenScript, Piscataway, NJ): Get A Quote

摘要

The adenosine analogue galidesivir (BCX4430), a broad-spectrum RNA virus inhibitor, has entered a phase 1 clinical safety and pharmacokinetics study in healthy subjects and is under clinical development for treatment of Ebola and yellow fever virus infections. Moreover, galidesivir also inhibits the reproduction of tick-borne encephalitis virus (TBEV) and numerous other medically important flaviviruses. Until now, studies of this antiviral agent have not yielded resistant viruses. Here, we demonstrate that an E460D substitution in the active site of TBEV RNA-dependent RNA polymerase (RdRp) confers resistance to galidesivir in cell culture. Galidesivir-resistant TBEV exhibited no cross-resistance to structurally... More

关键词

BCX4430; attenuation; drug resistance; galidesivir; mutation; tick-borne encephalitis virus